Masimo Corporation
Masimo Corporation Announces CEO Departure and Reaffirms Financial Guidance
Summary
On October 24, 2024, Masimo Corporation's Board of Directors terminated the employment of Chief Executive Officer Joe Kiani, effective immediately. Michelle Brennan has been appointed as Interim Chief Executive Officer. Masimo also reaffirmed its non-GAAP financial guidance for the third quarter and full fiscal year 2024, as previously announced. The company continues to evaluate strategic alternatives for its consumer segment.
Profitelligence Alerts
Get alerts for MASI
Be first to know when Masimo Corporation files with the SEC.
Filing Categories
Advertisement
About Masimo Corporation
Masimo Corporation is a global leader in noninvasive monitoring technologies, specifically focusing on developing innovative medical devices that improve patient outcomes and reduce the cost of care. The company's flagship product line includes advanced signal processing pulse oximetry devices, which are pivotal in accurately measuring oxygen levels, pulse rate, and other vital signals without the need for invasive procedures. Masimo's technology is widely adopted across various healthcare settings including hospitals, outpatient treatment centers, and alternative care sites, enhancing patient monitoring and aiding clinicians in detecting potential health issues more efficiently. Besides, Masimo’s products are recognized for their precision and reliability, demonstrating robustness even in challenging clinical environments where motion and low perfusion can affect monitoring accuracy. The corporation is committed to expanding its technological suite, covering a spectrum of health monitoring solutions that contribute to improved healthcare practices globally. Based in Irvine, California, Masimo's ongoing innovation continues to set benchmarks in the healthcare industry, influencing a wide range of sectors from emergency care to surgical and critical care monitoring.
Official SEC Documents
Advertisement